Maria Claudia Nogueira Zerbini

Dr. Maria Claudia Nogueira Zerbini

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2003 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
MFMaria Candida B. V. Fragoso
Maria Candida B. V. Fragoso
SDSorahia Domenice
Sorahia Domenice
ALAna Claudia Latronico
Ana Claudia Latronico
RMRegina Matsunaga Martin
Regina Matsunaga Martin
MPMaria Adelaide Albergaria Pereira
Maria Adelaide Albergaria Pereira
BMBerenice Bilharinho Mendonca
Berenice Bilharinho Mendonca
ACTH-independent macronodular adrenal hyperplasia (AIMAH) is an uncommon cause of Cushing's syndrome characterized by bilateral nodular adrenocortical hyperfunction in the presence of suppressed ACTH levels. We investigated whether activating mutations in the ACTH receptor (MC2-R) or G(s alpha) (GNAS1) genes might be involved in AIMAH genesis. Five women with Cushing's syndrome due to AIMAH, confirmed by histological studies, and no signs of McCune-Albright syndrome were selected for molecular analysis of these genes. The single exon of the MC2-R gene and exons 8 and 9 of the GNAS1 gene were amplified by PCR in genomic DNA from adrenal nodules and peripheral blood. Direct sequencing revealed only MC2-R wild-type sequences. GNAS1 PCR products at denaturing gradient gel electrophoresis revealed abnormal migration patterns in adrenal tissues of three patients. Automatic sequencing showed two different activating mutations at codon Arg(201) of GNAS1, a substitution by histidine in two cases and by serine in one case. In conclusion, we found two different gsp mutations in three patients with Cushing's syndrome due to AIMAH, and we speculate whether they belong to the spectrum of McCune-Albright syndrome or whether these are the first reported cases of AIMAH due to gsp mutations.

1 August 2014 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
GAGuilherme Asmar Alencar
Guilherme Asmar Alencar
ALAntonio Marcondes Lerario
Antonio Marcondes Lerario
MNMirian Yumie NISHI
Mirian Yumie NISHI
BMBeatriz Marinho de Paula Mariani
Beatriz Marinho de Paula Mariani
MAMadson Queiroz Almeida
Madson Queiroz Almeida
MFMaria Candida B. V. Fragoso
Maria Candida B. V. Fragoso
Context: Primary macronodular adrenal hyperplasia (PMAH) is a rare cause of Cushing's syndrome, usually characterized by functioning adrenal macronodules and increased cortisol production. Familial clustering of PMAH has been described, suggesting an inherited genetic cause for this condition. Objective: The aim of the present study was to identify the gene responsible for familial PMAH. Patients and Methods: Forty-seven individuals of a Brazilian family with PMAH were evaluated. A single-nucleotide polymorphism-based genome-wide linkage analysis followed by whole-exome sequencing were then performed in selected family members. Additionally, 29 other patients with PMAH and 125 randomly selected healthy individuals were studied to validate the genetic findings. Moreover, PMAH tissue was also analyzed through whole-exome sequencing, conventional sequencing, and microsatellite analysis. Results: A heterozygous germline variant in the ARMC5 gene (p.Leu365Pro) was identified by whole-exome sequencing in a candidate genomic region (16p11.2). Subsequently, the same variant was confirmed by conventional sequencing in all 16 affected family members. The variant was predicted to be damaging by in silico methods and was not found in available online databases or in the 125 selected healthy individuals. Seven additional ARMC5 variants were subsequently identified in 5 of 21 patients with apparently sporadic PMAH and in 2 of 3 families with the disease. Further molecular analysis identified a somatic mutational event in 4 patients whose adrenal tissue was available. Conclusions: Inherited autosomal dominant mutations in the ARMC5 gene are a frequent cause of PMAH. Biallelic inactivation of ARMC5 is consistent with its role as a potential tumor suppressor gene.

1 February 2005 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
CHClaudio L. Hashimoto
Claudio L. Hashimoto
KIKiyoshi Iriya
Kiyoshi Iriya
EBElisa R. Baba
Elisa R. Baba
TNTomas Navarro-Rodriguez
Tomas Navarro-Rodriguez
MZMaria Claudia Nogueira Zerbini
Maria Claudia Nogueira Zerbini
JMJoaquim Prado P. Moraes-Filho
Joaquim Prado P. Moraes-Filho
Patients with primary head and neck cancer show a predisposition to develop esophageal cancer. The aim of this study was to investigate in these patients: the prevalence of esophageal cancer comparing the value of chromoendoscopy using Lugol's solution examination to standard endoscopy, in the early diagnosis of esophageal cancer. Prospective observational study at a state general university hospital in Sao Paulo, Brazil. 326 consecutive adult patients with primary head and neck cancer were evaluated. A standard endoscopy was performed, followed by a 2% lugol's dye spray chromoendoscopy and histopathologic study. The prevalence of esophageal cancer was defined. The results of the two endoscopic methods were compared. Twenty-four patients with esophageal cancer and high-grade intraepithelial neoplasia were detected and had a prevalence of 7.36%. Chromoendoscopy and standard endoscopy were equivalent to the diagnosis of advanced and invasive esophageal cancer. However, standard endoscopy diagnosed 55% of high-grade intraepithelial neoplasia, in comparison to chromoendoscopy that detected 100%. Patients with primary head and neck cancer should be considered as high risks for the presence of esophageal cancer. Lugol's dye chromoendoscopy diagnosed high-grade intraepithelial neoplasia, which went unnoticed with standard endoscopy. It permits a more exact detection of lesion boundaries and facilitates a more precise targeting of biopsy fragments.

1 December 1995 in Journal of Urology
Verified
Journal Article
Closed access
BMBerenice Bilharinho Mendonca
Berenice Bilharinho Mendonca
ALAntonio Marmo Lucon
Antonio Marmo Lucon
CMClaudia A.V. Menezes
Claudia A.V. Menezes
LSLuis B. Saldanha
Luis B. Saldanha
ALAna C. Latronico
Ana C. Latronico
BWBernardo L. Wajchenberg
Bernardo L. Wajchenberg

1 January 2018 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
ICIsadora P. Cavalcante
Isadora P. Cavalcante
MNMirian Nishi
Mirian Nishi
MZMaria Claudia Nogueira Zerbini
Maria Claudia Nogueira Zerbini
MAMadson Q. Almeida
Madson Q. Almeida
VBVania B. Brondani
Vania B. Brondani
MFMaria Candida B.V. Fragoso
Maria Candida B.V. Fragoso

1 February 2015 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
STSergio P. A. Toledo
Sergio P. A. Toledo
DLDelmar M. Lourenço
Delmar M. Lourenço
TSTomoko Sekiya
Tomoko Sekiya
ALAntonio M. Lucon
Antonio M. Lucon
MBMarcos E. S. Baena
Marcos E. S. Baena
PDPatricia Dahia
Patricia Dahia
Context: The phenotype of familial pheochromocytoma (PHEO) associated with germline TMEM127 mutations (TMEM127-related PHEO) has not been clearly defined. Objective: This study aimed to investigate the penetrance, full phenotypic spectrum and effectiveness of clinical/genetic screening in TMEM127-related PHEO. Design, Setting, and Participants: Clinical and genetic screening, and genetic counseling were offered to 151 individuals from a six-generation family carrying a TMEM127 germline mutation in a referral center. Intervention and Main Outcome Measures: TMEM127 genetic testing was offered to at-risk relatives and clinical surveillance for pheochromocytoma was performed in mutation-positive carriers. Results: Forty seven individuals carried the c.410-2A>C TMEM127 mutation. Clinical data were obtained from 34 TMEM127-mutation carriers followed up for 8.7 ± 8.1 years (range, 1–20 y). Pheochromocytoma was diagnosed in 11 carriers (32%) at a median age of 43 years. In nine patients, symptoms started at 29 years (range, 10–55 y) and two cases were asymptomatic. Tumors were multicentric in five (45%) and bilateral in five (45%) patients. Six patients (54%) had at least one adrenomedullary nodule less than 10 mm. No paragangliomas, distant metastases, or other manifestations were detected. Cumulative penetrance of pheochromocytoma was 0% at 0–20 years, 3% at 21–30 years, 15% at 31–40 years, 24% at 41–50 years, and 32% at 51–65 years. The youngest case was diagnosed at 22 years and the earliest symptoms were reported at age 10. Conclusions: Tumor multicentricity, nodular adrenomedullary hyperplasia, and the occurrence of symptoms more than a decade earlier than the age at diagnosis are novel findings in TMEM127-related PHEO. The high penetrance of pheochromocytoma in this condition validates the benefits of genetic testing of at-risk relatives. We thus recommend that TMEM127 genetic testing should be offered to at-risk individuals at age 22 years and mutation carriers should undergo clinical surveillance annually.